The U.S. Food and Drug Administration [has] unveiled a new source of information for patients and health care professionals on the safety of recently approved drugs and biologics.
Summaries of FDA safety analyses on recently approved products will now be periodically prepared and posted on FDA’s website along with a brief discussion of the steps FDA is taking to address any identified safety issues.
Some side effects may not become apparent until after a medicine has been approved and becomes available to a larger, more diverse population than the patients who participated in clinical trials that supported approval. The new summaries provide a comprehensive look at safety data early in the product’s post-approval life cycle and are based on reports by manufacturers, providers, consumers and others to the FDA’s Adverse Event Reporting System (AERS) and the Vaccine Adverse Event Reporting System maintained by the FDA and the Center for Disease Control and Prevention; periodic safety information submitted to FDA by manufacturers; information contained in the medical literature; and data from ongoing drug and biologic studies.
Included in the summaries may be information on potentially serious, previously unidentified risks, if any are found during the review, as well as known adverse events that occur more often than they did during clinical studies. The summaries will also include a brief discussion of any steps FDA may be taking to address these safety issues.
The FreePint Family is a family of resources to help information workers be more effective, raise the value of information in their organisations and contribute to success.
'FreePint... provides most of my professional development because it won't come through work and [other resources] just don't cut it.'
FUMSI Forum: Do you have a research question? Post it to the FUMSI Forum, where professionals share Q&A and useful tips on how to Find, Use, Manage and Share Information. It's free.
FreePint Shop:
VIP LiveWire:
